ENTITY
Biogen Inc

Biogen Inc (BIIB US)

137
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
Refresh
bullishS&P 500 INDEX
06 Nov 2019 05:30

U.S. Equity Strategy: Small-Caps Testing Critical Resistance; Downgrading Communications

As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based...

Logo
398 Views
Share
06 Feb 2019 11:41

Biosimilar Battlefield: The Remsima/Inflectra Warning

2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...

Share
bearishS&P 500 INDEX
09 Jan 2019 03:12

U.S. Equity Strategy: Oversold Rally Continues

A combination of, optimism surrounding U.S.-China trade talks, and Fed Chairman Powell’s comments have led to a continuation of the oversold bounce...

Logo
572 Views
Share
29 Oct 2018 13:52

Smartkarma’s Week That Was in JP/​​​​KR: Market Turbulence 10 Years After 2008, Coway, & Celltrion

The Korean and Japanese stock markets have fallen sharply in October. Nikkei is down 12% and KOSPI is down 14% in October. It has been 10 years...

Logo
299 Views
Share
x